Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Van­da Phar­ma­ceu­ti­cals $VN­DA served up a hot stew of mixed da­ta for a slate of end­points re­lat­ed to what they called clear ev­i­dence that their mela­tonin sleep drug Het­lioz (tasimelteon) could help mil­lions of trav­el­ers suf­fer­ing from jet lag.

Nev­er mind that they couldn’t get a planned 90 peo­ple in the study, set­tling for 25 in­stead; Van­da CEO Mi­hael H. Poly­meropou­los said they were build­ing on a body of da­ta to prove it would help jet-lagged pa­tients look­ing for added sleep ben­e­fits. And that, they added, would be worth a ma­jor up­grade from the agency as they sought to tack­le a big mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.